Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Editor's Choice - Free Access

Antimicrobial Peptides – Promising Alternatives to Conventional Antibiotics

Baltzer S.A. · Brown M.H.

Author affiliations

School of Biological Sciences, Flinders University, Adelaide, S.A., Australia

Corresponding Author

Melissa Brown

School of Biological Sciences

Flinders University, GPO 2100

Adelaide, SA 5001 (Australia)

Tel. +61 8 8201 2747, E-Mail melissa.brown@flinders.edu.au

Related Articles for ""

J Mol Microbiol Biotechnol 2011;20:228–235

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Antimicrobial peptides (APs) have been described as evolutionary ancient weapons. Produced by a wide variety of organisms as part of a non-specific immune response, these peptides are involved in the direct destruction of various microorganisms. Several APs have been shown to have broad activity spectra against microorganisms such as Gram-positive and Gram-negative bacteria, enveloped viruses, fungi and parasites. Given that resistance to a number of antibiotics has developed in a wide range of microbes, the potential of APs as novel therapeutic agents is being evaluated. However, optimisation of APs designed for therapy will need to focus on such factors as their susceptibility to proteolytic degradation and reduction of toxicity to mammalian cells. Strict guidelines pertaining to their use should also be established to prevent or hinder future development of bacterial resistance to such peptides.

© 2011 S. Karger AG, Basel


  1. Aiello AE, Larson E: Antibacterial cleaning and hygiene products as an emerging risk factor for antibiotic resistance in the community. Lancet Infect Dis 2003;3:501–506.
    External Resources
  2. Alves ID, Correia I, Jiao CY, Sachon E, Sagan S, Lavielle S, Tollin G, Chassaing G: The interaction of cell-penetrating peptides with lipid model systems and subsequent lipid reorganization: thermodynamic and structural characterization. J Pept Sci 2009;15:200–209.
  3. Appelt C, Schrey AK, Soderhall JA, Schmieder P: Design of antimicrobial compounds based on peptide structures. Bioorg Med Chem Lett 2007;17:2334–2337.
  4. Arnold SR: Revenge of the killer microbe. Can Med Assoc J 2007;177:895–896.
    External Resources
  5. Bayer AS, Prasad R, Chandra J, Koul A, Smriti M, Varma A, Skurray RA, Firth N, Brown MH, Koo SP, Yeaman MR: In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect Immun 2000;68:3548–3553.
  6. Bell G, Gouyon PH: Arming the enemy: the evolution of resistance to self-proteins. Microbiology 2003;149:1367–1375.
  7. Bradshaw J: Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs 2003;17:233–240.
  8. Brown KL, Hancock RE: Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 2006;18:24–30.
  9. Brown KL, Mookherjee N, Hancock RE (eds): Antimicrobial, Host Defence Peptides and Proteins. Encyclopedia of Life Sciences. Chichester, Wiley, 2007, pp 1–11.
  10. Cherkasov A, Hilpert K, Jenssen H, Fjell CD, Waldbrook M, Mullaly SC, Volkmer R, Hancock REW: Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. Chem Biol 2009;4:65–74.
  11. Delves-Broughton J: Nisin as a food preservative. Food Aust 2005;57:525–527.
  12. Delves-Broughton J, Blackburn P, Evans RJ, Hugenholtz J: Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek 1996;69:193–202.
  13. Fox JL: The business of developing antibacterials. Nat Biotechnol 2006;24:1521–1528.
  14. Gottler LM, Ramamoorthy A: Structure, membrane orientation, mechanism, and function of pexiganan – a highly potent antimicrobial peptide designed from magainin. Biochim Biophys Acta 2009;1788:1680–1686.
  15. Guina T, Yi EC, Wang HL, Hackett M, Miller SI: A PhoP-regulated outer membrane protease of Salmonella enterica serovar Typhimurium promotes resistance to α-helical antimicrobial peptides. J Bacteriol 2000;182:4077–4086.
  16. Gunn JS: Bacterial modification of LPS and resistance to antimicrobial peptides. J Endotoxin Res 2001;7:57–62.
  17. Gunn JS, Lim KB, Krueger J, Kim K, Guo L, Hackett M, Miller SI: PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 1998;27:1171–1182.
  18. Guo L, Lim KB, Poduje CM, Daniel M, Gunn JS, Hackett M, Miller SI: Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell 1998;95:189–198.
  19. Hancock RE: Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001;1:156–164.
  20. Hancock RE: Concerns regarding resistance to self-proteins. Microbiology 2003;149:3343–3344.
  21. Hancock RE, Brown KL, Mookherjee N: Host defence peptides from invertebrates – emerging antimicrobial strategies. Immunobiology 2006;211:315–322.
  22. Hancock RE, Diamond G: The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 2000;8:402–410.
  23. Hancock RE, Sahl HG: Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006;24:1551–1557.
  24. Hawkey PM: The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008;62(suppl 1):i1–i9.
  25. Hawkey PM, Jones AM: The changing epidemiology of resistance. J Antimicrob Chemother 2009;64(suppl 1):i3–i10.
  26. Huang HW: Action of antimicrobial peptides: two-state model. Biochemistry 2000;39:8347–8352.
  27. Iwasaki T, Saido-Sakanaka H, Asaoka A, Taylor D, Ishibashi J, Yamakawa M: In vitroactivity of diasterimeric antimicrobial peptides alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. J Insect Biotechnol Sericol 2007;76:25–29.
  28. Izadpanah A, Gallo RL: Antimicrobial peptides. J Am Acad Dermacol 2005;52:381–390.
  29. Kaufmann BB, Hung DT: The fast track to multidrug resistance. Mol Cell 2010;37:297–298.
  30. Keymanesh K, Soltani S, Sardari S: Application of antimicrobial peptides in agriculture and food industry. World J Microbiol Biotechnol 2009;25:933–944.
    External Resources
  31. Kollef MH: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31:S131–S138.
  32. Lata S, Sharma BK, Raghava GP: Analysis and prediction of antibacterial peptides. BMC Bioinf 2007;8:263.
    External Resources
  33. Levy SB: Multidrug resistance – a sign of the times. N Engl J Med 1998;338:1376–1378.
  34. Livermore DM: Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003;36:S11–S23.
  35. Marr AK, Gooderham WJ, Hancock RE: Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006;6:468–472.
  36. Matsuzaki K: Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1999;1462:1–10.
  37. McEwen SA, Fedorka-Cray PJ: Antimicrobial use and resistance in animals. Clin Infect Dis 2002;34:S93–S106.
  38. Mohan KV, Rao SS, Atreya CD: Antiviral activity of selected antimicrobial peptides against vaccinia virus. Antiviral Res 2010;86:306–311.
  39. Monroe S, Polk R: Antimicrobial use and bacterial resistance. Curr Opin Microbiol 2000;3:496–501.
  40. Moore A: The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Rep 2003;4:114–117.
  41. Moskowitz SM, Ernst RK, Miller SI: PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004;186:575–579.
  42. Nakamura T, Furunaka H, Miyata T, Tokunaga F, Muta T, Iwanaga S, Niwa M, Takao T, Shimonishi Y: Tachyplesin, a class of antimicrobial peptides from the hemocytes of the horseshoe-crab (Tachypleus tridentatus) – isolation and chemical structure. J Biol Chem 1988;263:16709–16713.
  43. Perron GG, Zasloff M, Bell G: Experimental evolution of resistance to an antimicrobial peptide. Proc R Soc B 2006;273:251–256.
  44. Peschel A: How do bacteria resist human antimicrobial peptides? Trends Microbiol 2002;10:179–186.
  45. Peschel A, Collins LV: Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin. Peptides 2001;22:1651–1659.
  46. Powers JP, Hancock RE: The relationship between peptide structure and antibacterial activity. Peptides 2003;24:1681–1691.
  47. Renau TE, Leger R, Flamme EM, Sangalang J, She MW, Yen R, Gannon CL, Griffith D, Chamberland S, Lomovskaya O, Hecker SJ, Lee VJ, Ohta T, Nakayama K: Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem 1999;42:4928–4931.
  48. Roy H, Dare K, Ibba M: Adaptation of the bacterial membrane to changing environments using aminoacylated phospholipids. Mol Microbiol 2009;71:547–550.
  49. Sahl H, Peschel A: The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 2006;4:529–536.
    External Resources
  50. Samuelsen O, Haukland HH, Jenssen H, Kramer M, Sandvik K, Ulvatne H, Vorland LH: Induced resistance to the antimicrobial peptide lactoferricin B in Staphylococcus aureus. FEBS Lett 2005;579:3421–3426.
  51. Shafer WM, Qu X, Waring AJ, Lehrer RI: Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA 1998;95:1829–1833.
  52. Shai Y: Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999;1462:55–70.
  53. Shi YX, Cromie MJ, Hsu FF, Turk J, Groisman EA: PhoP-regulated Salmonella resistance to the antimicrobial peptides magainin 2 and polymyxin B. Mol Microbiol 2004;53:229–241.
  54. Spratt BG: Antibiotic resistance: counting the cost. Curr Biol 1996;6:1219–1221.
  55. Straus SK, Hancock RE: Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 2006;1758:1215–1223.
  56. Tanabe K, Lamping E, Adachi K, Takano Y, Kawabata K, Shizuri Y, Niimi M, Uehara Y: Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium. Biochem Biophys Res Commun 2007;364:990–995.
  57. Vizioli J, Salzet M: Antimicrobial peptides versus parasitic infections? Trends Parasitol 2002;18:475–476.
  58. Yang L, Weiss TM, Lehrer RI, Huang HW: Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J 2000;79:2002–2009.
  59. Yount NY, Bayer AS, Xiong YQ, Yeaman MR: Advances in antimicrobial peptide immunobiology. Biopolymers 2006;84:435–458.
  60. Zasloff M: Antimicrobial peptides of multicellular organisms. Nature 2002;415:389–395.

Article / Publication Details

First-Page Preview
Abstract of Review

Published online: September 02, 2011
Issue release date: October 2011

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 0

ISSN: 1464-1801 (Print)
eISSN: 1660-2412 (Online)

For additional information: https://www.karger.com/MMB

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.